# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.